CYTO — Cytophage Technologies Share Price
Last trade - 00:00- CA$15.10m
- CA$14.34m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.62 | ||
| Price to Tang. Book | 3.62 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -155.47% | ||
| Return on Equity | -285.56% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cytophage Technologies Ltd. is a Canadian biotechnology company. The Company uses advanced molecular genetic techniques and synthetic biology to create bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria, the Company generates customized phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a phage-display methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health. Its products include FarmPhage, AviPhage, PhageFend, and BoviPhage. FarmPhage is a water-soluble phage solution for livestock. AviPhage is poultry health products offered by the Company.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- September 3rd, 2019
- Public Since
- February 1st, 2022
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 53,935,221
- Address
- 26 Henlow Bay, WINNIPEG, R3Y 1G4
- Web
- Phone
- +1 4162144810
- Auditors
- McGovern Hurley LLP
Similar to CYTO
Aequus Pharmaceuticals
TSX Venture Exchange
Arch Biopartners
TSX Venture Exchange
Biosyent
TSX Venture Exchange
Decibel Cannabis
TSX Venture Exchange
Delivra Health Brands
TSX Venture Exchange
FAQ
As of Today at 19:09 UTC, shares in Cytophage Technologies are trading at CA$0.28. This share price information is delayed by 15 minutes.
Shares in Cytophage Technologies last closed at CA$0.28 and the price had moved by -61.68% over the past 365 days. In terms of relative price strength the Cytophage Technologies share price has underperformed the Toronto Stock Exchange 300 Composite Index by -67.53% over the past year.
There is no consensus recommendation for this security.
Find out moreCytophage Technologies does not currently pay a dividend.
Cytophage Technologies does not currently pay a dividend.
Cytophage Technologies does not currently pay a dividend.
To buy shares in Cytophage Technologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.28, shares in Cytophage Technologies had a market capitalisation of CA$15.10m.
Here are the trading details for Cytophage Technologies:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: CYTO
Based on an overall assessment of its quality, value and momentum Cytophage Technologies is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cytophage Technologies. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -30.13%.
As of the last closing price of CA$0.28, shares in Cytophage Technologies were trading -22.09% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cytophage Technologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.28.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Cytophage Technologies' directors